¼¼°èÀÇ Áßµ¶ Ä¡·áÇÐ ½ÃÀå
Addiction Therapeutics
»óǰÄÚµå : 1757939
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 281 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,053,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,161,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Áßµ¶ Ä¡·áÇÐ ½ÃÀåÀº 2030³â±îÁö 360¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 252¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Áßµ¶ Ä¡·áÇÐ ½ÃÀåÀº 2024-2030³â¿¡ CAGR 6.2%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 360¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¾ËÄÚ¿Ã Áßµ¶ Ä¡·áÇÐÀº CAGR 4.9%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 182¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´ã¹è Áßµ¶ Ä¡·áÇÐ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 7.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 69¾ï ´Þ·¯, Áß±¹Àº CAGR 9.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Áßµ¶ Ä¡·áÇÐ ½ÃÀåÀº 2024³â¿¡ 69¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 73¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 9.5%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.1%¿Í 6.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Áßµ¶ Ä¡·áÇÐ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Áßµ¶ Ä¡·áÇÐÀÌ °øÁߺ¸°Ç, ÇൿÀÇÇÐ, ÀǾàǰ Çõ½Å¿¡¼­ Àü·«Àû Á߿伺ÀÌ Ä¿Áö°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¿ÀÇÇ¿ÀÀ̵å Áßµ¶, ¾ËÄÚ¿Ã Áßµ¶, ´ÏÄÚÆ¾ Áßµ¶, °¢¼ºÁ¦ Áßµ¶°ú °°Àº ¾à¹° »ç¿ë Àå¾Ö(SUDs)ÀÇ ºÎ´ãÀÌ °è¼Ó Áõ°¡ÇÔ¿¡ µû¶ó Áßµ¶ Ä¡·á´Â Àü ¼¼°è º¸°ÇÀÇ ½Ã±ÞÇÑ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. Áßµ¶ÀÌ µµ´öÀû ½ÇÆÐ°¡ ¾Æ´Ñ ¸¸¼ºÀûÀÎ ½Å°æÇൿÇÐÀû »óŶó´Â ÀνÄÀÌ ³Î¸® ÆÛÁö¸é¼­ ¾à¸®ÇÐÀû °³ÀÔÀÌ Á¾ÇÕÀûÀÎ Ä¡·á Àü·«ÀÇ ÇÙ½ÉÀ¸·Î ¹Þ¾Æµé¿©Áö°í ÀÖ½À´Ï´Ù. °¥¸Á, ±Ý´Ü Áõ»ó ¹× Àç¹ß ¹æÁö¸¦ ¸ñÇ¥·Î ÇÏ´Â ¾à¹° Ä¡·á´Â ÀçȰ, Á¤½Å°ú ¹× 1Â÷ Áø·áÀÇ ¸ðµç ¿µ¿ª¿¡¼­ ÀÓ»óÀû ÁöÁö¸¦ ¹Þ°í ÀÖ½À´Ï´Ù.

ºÏ¹ÌÀÇ ¿ÀÇÇ¿ÀÀ̵å À§±â, À¯·´ÀÇ ¾ËÄÚ¿Ã Áßµ¶, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °¢¼ºÁ¦ ³²¿ë Áõ°¡·Î ÀÎÇØ °¢±¹ Á¤ºÎ´Â Áßµ¶ Ä¡·á¸¦ ±¹°¡Àû º¸°ÇÀÇ·á °úÁ¦·Î ¿ì¼±¼øÀ§¸¦ Á¤Çϰí ÀÖ½À´Ï´Ù. Á¤½Å°Ç°­ ¹®Á¦ Áõ°¡, °æÁ¦Àû ºÒ¾È, ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ °í¸³ µî º¸´Ù ±¤¹üÀ§ÇÑ »çȸÀû ¿äÀÎÀ¸·Î ÀÎÇØ Á¢±ÙÀÌ ¿ëÀÌÇϰí Áõ°Å¿¡ ±â¹ÝÇÑ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù. ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Áßµ¶ Ä¡·áÇÐÀº °ø°ø º¸Çè Á¦µµ, Á÷¿ø Áö¿ø ÇÁ·Î±×·¥, ¹ý¿ø¿¡¼­ °­Á¦ÇÏ´Â Ä¡·á ±¸»ó¿¡ ÅëÇյǰí ÀÖ½À´Ï´Ù.

Áßµ¶ Ä¡·áÀÇ ¾à¹° Çõ½ÅÀº ½Å°æ ¼ö¿ëü(¿ÀÇÇ¿ÀÀ̵å, µµÆÄ¹Î, GABA µî)¸¦ Á¶ÀýÇϰí, º¸»ó °æ·Î¸¦ Â÷´ÜÇϸç, ¿ì¿ïÁõ°ú ºÒ¾ÈÁõÀ» Æ÷ÇÔÇÑ ÀÌÁß Áø´ÜÀ» °ü¸®ÇÏ´Â ¾à¹° °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº ¹°Áú ÀÇÁ¸¼ºÀ» °¨¼Ò½Ãų »Ó¸¸ ¾Æ´Ï¶ó ½Å°æÇÐÀû ±ÕÇü°ú Çൿ ±â´ÉÀ» ȸº¹Çϵµ·Ï ¼³°èµÇ¾î ȸº¹ ÁöÇâÀû ÀÇ·á ¸ðµ¨¿¡¼­ Áß½ÉÀûÀÎ ¿ªÇÒÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

»õ·Î¿î ¸ÞÄ¿´ÏÁò, µðÁöÅÐ ÅëÇÕ, Á¤Ã¥ °³ÇõÀº Áßµ¶ Ä¡·áÇÐÀ» ¾î¶»°Ô ÁøÈ­½Ã۰í Àִ°¡?

½Å°æ¾à¸®ÇÐÀÇ ¹ßÀüÀ¸·Î Áßµ¶ Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎÀÌ È®ÀåµÇ°í ÀÖÀ¸¸ç, º¸´Ù Ç¥ÀûÈ­µÇ°í ³»¾à¼ºÀÌ ³ôÀº ÁßÀ縦 Á¦°øÇÕ´Ï´Ù. Àå±â Áö¼ÓÇü ÁÖ»çÁ¦, µðÆ÷Á¦Á¦, À̽ÄÇü µð¹ÙÀ̽º´Â ¼øÀÀµµ ¹®Á¦¸¦ ÇØ°áÇÏ°í ¿À³²¿ëÀÇ °¡´É¼ºÀ» ÁÙ¿©ÁÝ´Ï´Ù. º¸»ó ȸ·Î ºÎºÐ ÀÛ¿ëÁ¦, ±æÇ×Á¦, Á¶ÀýÁ¦´Â ¾ËÄڿðú ¿ÀÇÇ¿ÀÀ̵忡¼­ µµ¹Ú°ú °ÔÀÓ°ú °°Àº »õ·Î¿î Çൿ Áßµ¶¿¡ À̸£±â±îÁö ´Ù¾çÇÑ Áßµ¶¿¡ ´ëÇÑ ÀÓ»ó °³¹ßÀÌ ÁøÇà ÁßÀÔ´Ï´Ù.

¸ð¹ÙÀÏ °Ç°­ ¾Û, °¡»ó Çൿ Áö¿ø, AI¸¦ ÅëÇÑ ¼øÀÀµµ ¸ð´ÏÅ͸µ°ú °°Àº µðÁöÅÐ ÅøÀÇ ÅëÇÕÀº ¾à¹° Ä¡·áÀÇ È¿°ú¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº ¾à¹° º¹¿ë ¾Ë¸², °¥¸Á ÃßÀû, °¡»ó Ä¡·á Áö¿øÀ» ¿ëÀÌÇÏ°Ô Çϰí, ¾à¸®ÇÐÀû Ä¡·á¿Í ½É¸®»çȸÀû Ä¡·á¸¦ ÅëÇÕÇÑ ÇÏÀ̺긮µå Ä¡·á ¸ðµ¨À» Á¦°øÇÕ´Ï´Ù. µðÁöÅÐ Ä¡·á(DTx)´Â ƯÈ÷ ¿ø°ÝÀÇ·á°¡ µµÀÔµÈ ½ÃÀå°ú °¡Ä¡ ±â¹Ý Ä¡·á ¸ðµ¨¿¡ ´ëÇÑ ÁöºÒÀÚÀÇ Áö¿øÀÌ ÀÖ´Â ½ÃÀå¿¡¼­ 󹿾à°ú °áÇÕÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Á¤Ã¥ °³ÇõÀ¸·Î Áßµ¶ Ä¡·áÁ¦¿¡ ´ëÇÑ ¿À·£ Á¢±Ù À庮ÀÌ Á¦°ÅµÇ°í ÀÖ½À´Ï´Ù. °£È£»ç¿¡°Ô ó¹æ±Ç È®´ë, ƯÁ¤ ¾à¹°¿¡ ´ëÇÑ »ó´ã Àǹ«È­ Ãà¼Ò, º´¿ë¿ä¹ý¿¡ ´ëÇÑ »óȯ ÇÕ¸®È­ µîÀÌ Áßµ¶ Ä¡·áÁ¦ÀÇ Á¢±ÙÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦ ´ç±¹Àº Áßµ¶ À§±âÀÇ ±ä±Þ¼ºÀ» ÀνÄÇϰí ȹ±âÀûÀÎ Ä¡·áÁ¦ÀÇ ½Å¼ÓÇÑ ½ÂÀÎÀ» À§ÇØ ÆÐ½ºÆ® Æ®·¢ Á¦µµ¿Í ¿ì¼± ½É»ç Á¦µµ¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °³ÇõÀº Á¶±â °³ÀÔÀ» ÃËÁøÇϰí, ³«ÀÎÀ» ÁÙÀ̰í, ¡¹úÀû Á¢±Ùº¸´Ù ÇÇÇØ °¨¼Ò¸¦ ¿ì¼±½ÃÇÔÀ¸·Î½á Ä¡·á ȯ°æÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù.

Áßµ¶ Ä¡·áÇÐÀÇ ¼ºÀåÀ» ÁÖµµÇϴ ȯÀÚ±º, Ä¡·á ¼ö´Ü, Áö¿ª ½ÃÀåÀº?

ÁÖ¿ä ȯÀÚ±º¿¡´Â ¿ÀÇÇ¿ÀÀÌµå »ç¿ë Àå¾Ö(OUD) ȯÀÚ°¡ Æ÷ÇԵǸç, ƯÈ÷ ¹Ì±¹°ú ij³ª´Ù¿¡¼­ ÇöÀç Ä¡·áÁ¦ÀÇ ÁÖ¿ä ÃÊÁ¡ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¾ËÄÚ¿Ã »ç¿ë Àå¾Ö(AUD)´Â ƯÈ÷ À¯·´°ú ¶óƾ¾Æ¸Þ¸®Ä« ÀϺΠÁö¿ª¿¡¼­ Àü ¼¼°è Ä¡·á ¼ö¿äÀÇ »ó´ç ºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù. 󹿾à°ú ÀϹÝÀǾàǰÀ» Æ÷ÇÔÇÑ ±Ý¿¬Ä¡·áÁ¦´Â ¸ðµç Áö¿ª¿¡¼­ ±¤¹üÀ§ÇÏ°í ±¤¹üÀ§ÇÑ Á¢±Ù¼ºÀ» °¡Áø ºÐ¾ßÀ̱⵵ ÇÕ´Ï´Ù.

Ä¡·á ¹æ¹ýÀº ÇØµ¶ Áö¿ø ¹× À¯Áö ¿ä¹ýºÎÅÍ Àç¹ß ¿¹¹æ ¹× ÀÌÁß Áø´Ü °ü¸®±îÁö ´Ù¾çÇÕ´Ï´Ù. ÀϹÝÀûÀÎ ¾à¸®ÇÐÀû ¾à¹°¿¡´Â ¸ÞŸµ·, ºÎÇÁ·¹³ë¸£ÇÉ, ³ªÆ®·º¼Õ, ¾ÆÄ¯ÇÁ·Î¼¼ÀÌÆ®, µð¼³ÇǶ÷, ¹Ù·¹´ÏŬ¸° µîÀÌ ÀÖÀ¸¸ç, °¢°¢ ƯÁ¤ ¹°Áú ÀÇÁ¸¼º ¹× ȯÀÚ ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó ´Ù¸¨´Ï´Ù. »õ·Î¿î Ä¡·á¹ýÀ¸·Î´Â Ä«³ªºñ³ëÀÌµå ±â¹Ý Ä¡·á¹ý, ȯ°¢ º¸Á¶ ÁßÀç, »õ·Î¿î ½Å°æÇÐÀû Ç¥ÀûÀ» °¡Áø Ç×°¥¸ÁÁ¦ µîÀÌ ÀÖ½À´Ï´Ù.

ºÏ¹Ì°¡ Áßµ¶Ä¡·áÁ¦ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ´Â ÀÌÀ¯´Â dzºÎÇÑ ÇコÄɾî ÀÚ±Ý, ÁøÇà ÁßÀÎ °øÁߺ¸°Ç À§±â, ÷´ÜÈ­µÈ ÀÓ»ó ÀÎÇÁ¶ó¸¦ ±â¹ÝÀ¸·Î Çϰí ÀÖ½À´Ï´Ù. À¯·´Àº º¸ÆíÀû ÀǷẸÇèÁ¦µµ¿Í ÷´ÜÀÎ ¾à¹° Á¤Ã¥ ȯ°æ¿¡ ÈûÀÔ¾î ±Ù¼ÒÇÑ Â÷ÀÌ·Î ±× µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â ƯÈ÷ ¾ËÄڿðú °¢¼ºÁ¦ ³²¿ë¿¡ ½Ã´Þ¸®´Â µµ½Ã Áö¿ª¿¡¼­ µµÀÔÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ³«ÀÎ, Àü¹® ÀÇ·á ±â°ü¿¡ ´ëÇÑ Á¢±Ù¼º Á¦ÇÑ, º¸Çè Àû¿ë ¹üÀ§ÀÇ Á¦ÇÑ µîÀÌ ½ÅÈï ½ÃÀå¿¡¼­´Â ¿©ÀüÈ÷ À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

Áßµ¶Ä¡·áÇÐÀº ¹Ì·¡ÀÇ ÀÇ·á ½Ã½ºÅÛ, »çȸ ȸº¹·Â, Á¤½Å½Å°æÀÇÇÐ Çõ½ÅÀÇ Çü¼º¿¡ ÀÖÀ¸¸ç, ¾î¶² Àü·«Àû ¿ªÇÒÀ» ÇÒ ¼ö Àִ°¡?

Áßµ¶ Ä¡·áÇÐÀº ÅëÇÕÀûÀÌ°í °á°ú Áß½ÉÀûÀÌ¸ç »çȸÀûÀ¸·Î ¹ÝÀÀÇÏ´Â Ä¡·á ¸ðµ¨·Î ÀÇ·á ½Ã½ºÅÛÀ» ÀüȯÇÏ´Â µ¥ ÀÖÀ¸¸ç, Àü·«Àû ¿ªÇÒÀ» ÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù. Áßµ¶, Á¤½Å°Ç°­, »çȸÀû °áÁ¤ ¿äÀÎÀÇ ¿¬°ü¼ºÀÌ ¹àÇôÁü¿¡ µû¶ó ¾à¸®ÇÐÀûÀÎ °³ÀÔÀº ÁÖ°Å, °í¿ë, µ¿·á Áö¿ø, »ç¹ý °³Çõ¿¡ °ÉÄ£ ±¤¹üÀ§ÇÑ È¸º¹ »ýŰ迡 ÅëÇյǰí ÀÖ½À´Ï´Ù.

Á¦¾àȸ»ç¿Í »ý¸í°øÇÐ ±â¾÷Àº ÀÌ·¯ÇÑ ¸ð¸àÅÒÀ» Ȱ¿ëÇÏ¿© ¿Ü»ó ÈÄ ½ºÆ®·¹½º Àå¾Ö, ¿ÀÇÇ¿ÀÀÌµå ºñº¹¿ë ¸¸¼ºÅëÁõ, ½Å°æ Àç»ý µî ÀÎÁ¢ÇÑ Ä¡·á ¿µ¿ªÀ» ޱ¸ÇÏ¸ç ±âÁ¸ Áßµ¶ Ä¡·á¸¦ ³Ñ¾î Çõ½ÅÀÇ ÁöÆòÀ» ³ÐÇô°¡°í ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç±â°ü, º¸Çè»ç, ±â¼ú ±â¹Ý Ä¡·á ÇÁ·Î¹ÙÀÌ´õ°¡ Âü¿©ÇÏ´Â °øµ¿ ÀÚ±Ý Áö¿ø ¸ðµ¨Àº µ¥ÀÌÅͰ¡ dzºÎÇϰí ȯÀÚ Áß½ÉÀÇ ¸ÂÃã Ä¡·á Á¢±Ù¹ýÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

»çȸÀû ŵµ°¡ ¹üÁËÈ­¿¡¼­ ¹è·Á¿Í °úÇп¡ ±â¹ÝÇÑ Ä¡·á·Î º¯È­ÇÏ´Â °¡¿îµ¥, Áßµ¶ Ä¡·áÇÐÀº ¼¼°è »ê¾÷ ºÐ¼®°¡µéÀÌ ¾à¹° °ü·Ã Àå¾Ö¿Í Çൿ °Ç°­ Àå¾Ö¸¦ Ä¡·áÇϰí ÀνÄÇÏ°í ±Ã±ØÀûÀ¸·Î ¿¹¹æÇÏ´Â ¹æ¹ý¿¡ ´ëÇÑ ¼¼°è º¯È­ÀÇ Ãʼ®ÀÌ µÉ ¼ö Àִ°¡?

ºÎ¹®

À¯Çü(¾ËÄÚ¿Ã Áßµ¶ Ä¡·áÇÐ, ´ã¹è Áßµ¶ Ä¡·áÇÐ, ¾à¹° Áßµ¶ Ä¡·áÇÐ); À¯Åë ä³Î(º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ±âŸ À¯Åë ä³Î)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÇÕ°è 44 ÁÖ¸ñ)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø·Î ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Addiction Therapeutics Market to Reach US$36.0 Billion by 2030

The global market for Addiction Therapeutics estimated at US$25.2 Billion in the year 2024, is expected to reach US$36.0 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Alcohol Addiction Therapeutics, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$18.2 Billion by the end of the analysis period. Growth in the Tobacco Addiction Therapeutics segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.9 Billion While China is Forecast to Grow at 9.5% CAGR

The Addiction Therapeutics market in the U.S. is estimated at US$6.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.3 Billion by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Addiction Therapeutics Market - Key Trends & Drivers Summarized

Why Are Addiction Therapeutics Gaining Strategic Significance Across Public Health, Behavioral Medicine, and Pharmaceutical Innovation?

Addiction therapeutics are becoming a global health imperative as the burden of substance use disorders (SUDs)-including opioid, alcohol, nicotine, and stimulant dependencies-continues to rise. With addiction now widely recognized as a chronic neurobehavioral condition rather than a moral failing, there is growing acceptance of pharmacological intervention as a core component of comprehensive treatment strategies. Therapeutics aimed at managing cravings, withdrawal symptoms, and relapse prevention are gaining clinical traction across rehabilitation, psychiatric, and primary care settings.

The opioid crisis in North America, alcohol dependence in Europe, and increasing stimulant abuse in Asia-Pacific have prompted governments to prioritize addiction treatment under national healthcare agendas. Broader social drivers-such as rising mental health challenges, economic insecurity, and pandemic-induced isolation-are further amplifying the urgency of accessible, evidence-based treatment solutions. As demand escalates, addiction therapeutics are being integrated into public insurance schemes, employee assistance programs, and court-mandated treatment initiatives.

Pharmaceutical innovation in addiction therapy is also gaining momentum, with efforts focused on developing drugs that modulate neuroreceptors (e.g., opioid, dopamine, GABA), block reward pathways, and manage dual diagnoses involving depression or anxiety. These treatments are being designed not only to reduce substance dependence but also to restore neurological balance and behavioral function, highlighting their centrality in recovery-oriented healthcare models.

How Are Novel Mechanisms, Digital Integration, and Policy Reforms Driving the Evolution of Addiction Therapeutics?

The addiction therapeutics pipeline is expanding through advances in neuropharmacology, offering more targeted and tolerable interventions. Long-acting injectables, depot formulations, and implantable devices are addressing adherence challenges and reducing misuse potential. Partial agonists, antagonists, and modulators of reward circuitry are under clinical development for a wide spectrum of addictions-ranging from alcohol and opioids to emerging behavioral addictions like gambling and gaming.

Integration of digital tools-including mobile health apps, virtual behavioral support, and AI-driven adherence monitoring-is enhancing the effectiveness of pharmacotherapy. These tools facilitate medication reminders, craving tracking, and virtual therapy support, offering a hybrid care model that blends pharmacological and psychosocial treatment. Digital therapeutics (DTx) are increasingly paired with prescription drugs, particularly in markets with strong telehealth adoption and payer support for value-based care models.

Policy reforms are removing longstanding access barriers to addiction medications. Expansion of prescribing rights to nurse practitioners, reduction of mandatory counseling requirements for certain medications, and streamlining of reimbursement for combination therapies are catalyzing uptake. Additionally, regulatory bodies are accelerating approvals for breakthrough therapies under fast-track or priority review programs, recognizing the urgency of the addiction crisis. These reforms are reshaping the treatment landscape by promoting early intervention, reducing stigma, and prioritizing harm reduction over punitive approaches.

Which Patient Populations, Treatment Modalities, and Regional Markets Are Driving the Growth of Addiction Therapeutics?

Key patient groups include individuals with opioid use disorder (OUD), which remains the primary focus of current therapeutics, particularly in the U.S. and Canada. Alcohol use disorder (AUD) accounts for a substantial share of treatment demand globally, especially in Europe and parts of Latin America. Tobacco cessation products, including both prescription medications and over-the-counter options, also represent a high-volume, broad-access segment across all geographies.

Treatment modalities range from detoxification support and maintenance therapy to relapse prevention and dual-diagnosis management. Common pharmacological agents include methadone, buprenorphine, naltrexone, acamprosate, disulfiram, and varenicline, each aligned with specific substance dependencies and patient profiles. Emerging modalities include cannabinoid-based therapies, psychedelic-assisted interventions, and anti-craving agents with novel neurological targets.

North America leads the addiction therapeutics market due to robust healthcare funding, ongoing public health crises, and advanced clinical infrastructure. Europe follows closely, supported by universal healthcare systems and progressive drug policy environments. Asia-Pacific is showing increasing adoption, particularly in urban centers grappling with alcohol and stimulant abuse. However, stigma, limited access to specialized providers, and variable insurance coverage remain barriers in emerging markets.

What Strategic Role Will Addiction Therapeutics Play in Shaping Future Health Systems, Societal Resilience, and Neuropsychiatric Care Innovation?

Addiction therapeutics are poised to play a strategic role in transitioning healthcare systems toward integrated, outcomes-focused, and socially responsive models of care. As the link between addiction, mental health, and social determinants becomes more evident, pharmacological interventions are being embedded into broader ecosystems of recovery-spanning housing, employment, peer support, and justice reform.

Pharmaceutical and biotech players are leveraging this momentum to explore adjacent therapeutic areas such as post-traumatic stress disorder, chronic pain without opioids, and neuroregeneration-expanding the innovation horizon beyond conventional addiction treatment. Collaborative funding models involving public health agencies, insurers, and tech-enabled care providers are enabling a data-rich, patient-centered approach to treatment personalization.

With societal attitudes shifting from criminalization to compassion and science-driven care, could addiction therapeutics become the cornerstone of a global transformation in how we treat, perceive, and ultimately prevent substance-related and behavioral health disorders?

SCOPE OF STUDY:

The report analyzes the Addiction Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Alcohol Addiction Therapeutics, Tobacco Addiction Therapeutics, Drug Addiction Therapeutics); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â